Key Points
- Insider Neil Gregory Almstead sold 35,572 shares of PTC on Nov. 24 at an average $80.18 for about $2.85M, reducing his stake to 100,625 shares (a 26.12% cut); he also sold 71,928 shares on Nov. 25 and 55,000 on Oct. 3.
- PTC posted an earnings beat with $0.20 EPS vs. an expected -$1.19 and revenue of $211.0M vs. $177.4M, marking a turnaround from prior-year losses.
- Shares are trading up roughly 4% with a market cap near $6.92B; analysts hold a consensus "Moderate Buy" and a $75.40 target amid mixed ratings (10 Buy, 6 Hold, 1 Sell).
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Allan Steven Jacobson sold 11,801 shares of the company's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $80.14, for a total transaction of $945,732.14. Following the completion of the sale, the director directly owned 17,451 shares of the company's stock, valued at $1,398,523.14. The trade was a 40.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Allan Steven Jacobson also recently made the following trade(s):
- On Tuesday, November 25th, Allan Steven Jacobson sold 14,199 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.55, for a total value of $1,186,326.45.
- On Friday, October 3rd, Allan Steven Jacobson sold 12,000 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.00, for a total value of $780,000.00.
- On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.15, for a total value of $83,600.05.
- On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.15, for a total value of $83,600.05.
PTC Therapeutics Stock Performance
NASDAQ PTCT opened at $86.25 on Thursday. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The stock's 50 day moving average price is $68.42 and its two-hundred day moving average price is $56.44. The stock has a market capitalization of $6.92 billion, a price-to-earnings ratio of 12.37 and a beta of 0.60.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.
Analyst Upgrades and Downgrades
PTCT has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 target price on shares of PTC Therapeutics in a report on Wednesday, September 3rd. Wells Fargo & Company raised their target price on shares of PTC Therapeutics from $73.00 to $93.00 and gave the company an "overweight" rating in a research note on Wednesday, November 5th. Robert W. Baird set a $70.00 price target on shares of PTC Therapeutics in a research note on Friday, August 8th. Jefferies Financial Group boosted their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a "buy" rating in a research note on Tuesday, October 28th. Finally, Wall Street Zen upgraded shares of PTC Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, November 8th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $75.40.
Get Our Latest Report on PTC Therapeutics
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC lifted its position in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 236 shares during the last quarter. Optiver Holding B.V. increased its stake in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 249 shares during the period. Comerica Bank lifted its holdings in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 469 shares during the last quarter. Quantbot Technologies LP boosted its stake in PTC Therapeutics by 545.5% in the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 551 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 320 shares in the last quarter.
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
